Regeneron Pharmaceuticals, Inc. (REGN)
| Market Cap | 67.46B |
| Revenue (ttm) | 14.25B |
| Net Income (ttm) | 4.58B |
| Shares Out | 102.60M |
| EPS (ttm) | 41.59 |
| PE Ratio | 15.81 |
| Forward PE | 14.17 |
| Dividend | $3.52 (0.54%) |
| Ex-Dividend Date | Nov 20, 2025 |
| Volume | 688,281 |
| Open | 650.35 |
| Previous Close | 646.87 |
| Day's Range | 640.99 - 658.21 |
| 52-Week Range | 476.49 - 834.42 |
| Beta | 0.39 |
| Analysts | Buy |
| Price Target | 782.62 (+19.02%) |
| Earnings Date | Oct 28, 2025 |
About REGN
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq... [Read more]
Financial Performance
In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.
Financial StatementsAnalyst Summary
According to 21 analysts, the average rating for REGN stock is "Buy." The 12-month stock price target is $782.62, which is an increase of 19.02% from the latest price.
News
Press Release: ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
Regeneron Announces Investor Conference Presentations
TARRYTOWN, N.Y., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award
Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic conditions
Regeneron Q3 Earnings Review: This Is The Start Of A Dupixent Driven Comeback
Regeneron Pharmaceuticals, Inc. delivered a strong Q3 earnings beat, driven by Dupixent growth, despite ongoing Eylea sales declines and manufacturing setbacks. REGN's future growth is anchored by Dup...
Market Starting To Embrace The 'New' Regeneron
Regeneron Pharmaceuticals, Inc. beat Q3 revenue and EPS expectations, and it appears investors are finally embracing the fact the Eylea franchise is no longer a growth product. Eylea franchise faces o...
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2025 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis Leo...
Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Tuesday reported third-quarter adjusted earnings of $11.83 per share, down 5% year-over-year, beating the consensus of $9.59.
Regeneron beats quarterly estimates on strong demand for Dupixent
Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its eczema treatment, Dupixent, and cancer treatment Libtayo, sending its shares ...
Regeneron Reports Third Quarter 2025 Financial and Operating Results
TARRYTOWN, N.Y., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2025 and provided a business update.
Has Regeneron Stock Quietly Become A Value Buy?
Here is why we believe Regeneron Pharmaceuticals (REGN) stock is worthy of consideration as a value investment. It is presently trading nearly 38% lower than its one-year peak, and is also being trade...
Smart Acquisitions And Profit Margin Growth Amid Strategic Repositioning
We purchased several new fund holdings across various sectors. Sempra has been shifting its strategic focus from its highly regulated California operations to its growing presence in Texas. Regeneron ...
7 Stocks Taking The Next Step To Be On Offense
Bio-Rad Laboratories was a positive contributor after the company reported steadier earnings than the market expected. PVH also remains our largest share repurchaser for the year after buying a teens ...
Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
Positive opinion based on results of Phase 3 C-POST trial that show Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence...
Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers
New safety and pharmacokinetic data from Phase 3 C-POST trial provide insights on an every 6-week dosing regimen of adjuvant Libtayo® (cemiplimab) in high-risk cutaneous squamous cell carcinoma New sa...
DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss
Nearly all participants (11 of 12) experienced clinically meaningful hearing improvements, including three who achieved normal hearing; eight with longer follow-up showed stability or continued improv...
What If You Were Missing The Value In Regeneron Pharmaceuticals Stock?
Here's why we believe Regeneron Pharmaceuticals (REGN) stock merits attention as a value addition. Currently, it is trading almost 44% lower than its 1-year peak and is also priced at a PS multiple be...
US FDA expands use of Regeneron's Libtayo as add-on treatment for skin cancer
The U.S. Food and Drug Administration on Wednesday cleared Regeneron Pharmaceuticals' immunotherapy, Libtayo, as an add-on treatment for skin cancer patients at high risk of their disease returning af...
Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0....
11 Cheap Stocks for a Market That's Too Expensive
Amid a pricey market, Evercore wanted to find stocks that are less pricey but have staying power. Here's how they did it and what they found.
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
Regeneron: Growth Catalysts Incoming
Regeneron Pharmaceuticals, Inc. is rated a Buy, supported by strong Dupixent and oncology growth offsetting Eylea/Eylea HD declines. REGN's robust pipeline, best-in-class products, and upcoming patent...
Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025
TARRYTOWN, N.Y., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2025 financial and operating results on Tuesday...
Final Trades: Nvidia, Amphenol, Regeneron and Lockheed Martin
CNBC's "Halftime Report" team detail their stock picks and final trades.
Regeneron: Strong R&D Pipeline Drives Growth Outlook
Retail investors' fears over the launch of Eylea biosimilars are gradually fading amid the strong performance of Dupixent and Libtayo, actively gaining share in the PD-1 and PD-L1 inhibitors market. S...
Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol
FDA approval extends the indication of Evkeeza to treat younger patients with homozygous hypercholesterolemia (HoFH) HoFH is an inherited condition characterized by extremely high levels of low-densit...